Product Pathways - Tyrosine Kinase / Adaptors
LRIG1 Antibody #12752
|12752S||100 µl (10 western blots)||---||In Stock||---|
|12752||carrier free and custom formulation / quantity||email request|
Already purchased this product? Write a Review.
Species cross-reactivity is determined by western blot.
Applications Key: W=Western Blotting, IP=Immunoprecipitation
Species predicted to react based on 100% sequence homology: Monkey.
Specificity / Sensitivity
LRIG1 Antibody recognizes endogenous levels of total LRIG1 protein.
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human LRIG1 protein. Antibodies are purified by protein A and peptide affinity chromatography.
Leucine-rich immunoglobulin repeats 1 (LRIG1) is a type I transmembrane protein containing 15 leucine rich repeats and three immunoglobulin domains in the extracellular domain. Researchers characterize LRIG1 as a negative regulator of receptor tyrosine kinase signaling. In studies with ErbB family members and Met kinase, LRIG regulates signaling by increasing ubiquitination and lysosomal degradation of the receptors (1,2). Additional work indicates that LRIG1 plays a role in neurotropic signaling by negatively regulating Ret signaling (3,4). Expression profile studies demonstrate that LRIG1 is a marker in the quiescent population of stem cells in the intestine (5). Interestingly, the genetic ablation of one allele of LRIG1 in mice with an APC+/- background results in development of highly dysplastic adenomas, indicating a role for LRIG1 in tumor suppression (1). Indeed, down-regulation of LRIG1 is tentatively involved in tumor aggressiveness in several tumor types, including glioma (6), head and neck cancer (7), and cervical adenocarcinoma (8).
- Powell, A.E. et al. (2012) Cell 149, 146-58.
- Segatto, O. et al. (2011) J Cell Sci 124, 1785-93.
- Shattuck, D.L. et al. (2007) Mol Cell Biol 27, 1934-46.
- Ledda, F. et al. (2008) J Neurosci 28, 39-49.
- Muñoz, J. et al. (2012) EMBO J 31, 3079-91.
- Mao, F. et al. (2013) Int J Oncol 42, 1081-7.
- Sheu, J.J. et al. (2013) Oncogene , .
- Muller, S. et al. (2013) Int J Oncol 42, 247-52.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.